TickerTalks
Browse all tickers →
TickerTalks›$QGEN
QGQGEN

Qiagen N.V.

$QGEN·$9.4B·Medical - Diagnostics & Research·Healthcare
$46.17+1.3%YTD-4.0%1Y-2.8%
Price updated 15h ago·X counts updated 5d ago
QGQGEN
$QGENQiagen N.V.
$46.17+1.34%32 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $QGEN on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

32X posts · last 7 days
Sep 28Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $QGEN's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $QGEN — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Qiagen printing modest beats on diagnostics, FDA cleared the bloodstream infection panel — the slow compounder waiting for its own quarter.

Qiagen has delivered one of the most predictable diagnostic-industry profiles — four quarterly EPS beats of -0.4% to +5%, revenue growth of 0.3-6% YoY, and the September 28 FDA clearance of the QIAstat-Dx bloodstream-infection panel adds a new product-line revenue stream.

  • Q2 revenue of $535M was up 0.3% YoY — the growth deceleration is real, but the EPS cadence is intact (Q2 EPS $0.62 beat $0.598 by 3.7%, Q4 2025 was 4.9% above).
  • The October 2 QIAmini automation launch for small-batch sample preparation plus the September 24 workflow announcement show the product cycle is active; sell-side 2026 EPS of $2.43 steps to $2.61 in 2027 and $2.86 in 2028, implying 8-10% EPS growth.
  • At $44.75 and 48% of the 52-week range, the forward multiple on 2026 EPS of $2.43 is 18.4x — reasonable for a diagnostic-consumables company with 62% gross margins and 25% operating margins.

The November 3 Q3 earnings is the next catalyst — a continuation of the mid-single-digit revenue growth plus any update on QIAstat-Dx adoption pace would extend the current multiple; the broader diagnostic-industry multiple compression is the sector-wide variable.

What to watch: November 3 Q3 earnings and 2027 revenue trajectory; QIAstat-Dx bloodstream-infection panel adoption at hospital systems; QIAmini automation customer-win disclosures.

On the calendar: Q3 earnings scheduled 2026-11-03

Read the AI verdict on $QGEN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Qiagen makes sample preparation kits and molecular diagnostic assays used in hospitals, research labs, and pharmaceutical development.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $QGEN.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $QGEN

Partial — Qiagen makes sample preparation kits and molecular diagnostic assays used in hospitals, research labs, and pharmaceutical development.

Industry benchmark

19-name peer basket
+38.8%YTD
+56.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
21.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
25.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
11.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
61.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.62$0.60+3.7%
Q1 2026May 6, 2026$0.54$0.54-0.4%
Q4 2025Feb 4, 2026$0.62$0.61+1.6%
Q3 2025Nov 4, 2025$0.64$0.61+4.9%
Next earningsTue, Nov 3·consensus EPS $0.62

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$535.0M+0.3%63.6%24.7%$0.50$157.8M
Q1 FY26$492.3M+1.8%62.9%23.7%$0.33$53.7M
Q4 FY25$540.4M+3.7%58.7%28.5%$0.52$117.2M
Q3 FY25$532.6M+6.1%62.2%24.3%$0.60$119.0M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.1B$2.1B – $2.1B$2.43$2.38 – $2.4413
FY27$2.2B$2.2B – $2.3B$2.61$2.57 – $2.6913
FY28$2.4B$2.3B – $2.4B$2.86$2.71 – $2.9813
FY29$2.5B$2.5B – $2.5B$3.06$3.01 – $3.1111
FY30$2.6B$2.6B – $2.6B$3.30$3.23 – $3.356

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.52%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+4.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 204.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.615-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 9 other (7 6-Ks · 1 13G · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosisbusinesswire.com·3d agoQIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discoverybusinesswire.com·10d agoQIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panelzacks.com·14d agoQiagen N.V. $QGEN Shares Sold by Envestnet Asset Management Inc.defenseworld.net·15d agoQIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panelbusinesswire.com·18d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$ILMN$TMO$GH$NTRA$DHR$GRAL
Voices on X · last 7 days

No standout posts about $QGEN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport